{"entity":{"id":"neogenomics-pantracer","kind":"drug","name":"PanTracer","aka":["NeoGenomics PanTracer","NEO PanTracer Tissue","NEO PanTracer Pro","NEO PanTracer LBx"],"tldr":"NeoGenomics' family of large gene tests for solid tumours, from a tissue sample or a blood draw.","summary":"PanTracer is NeoGenomics' portfolio of comprehensive genomic profiling tests for solid tumours. PanTracer Tissue sequences 517 genes in DNA and RNA for single-nucleotide variants, insertions and deletions, copy number changes, RNA fusions and splice variants, with microsatellite instability and tumour mutational burden, in 8 to 10 days; PanTracer Tissue + HRD adds a homologous recombination deficiency score (BRCA1/2 and a genomic instability score from loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions), validated for primary epithelial ovarian tumours; PanTracer Pro adds HRD and cancer-type-directed immunohistochemistry to the tissue test in one order. PanTracer LBx sequences 514 genes from circulating tumour DNA in 7 days, without RNA sequencing or HRD. NeoGenomics lists PanTracer Tissue and Pro as New York approved, and the HRD and LBx tests as not.","status":"established","asOf":"2026-11-03","links":[{"label":"NeoGenomics: PanTracer portfolio","url":"https://www.neogenomics.com/providers/oncology-solutions/pantracer-portfolio"},{"label":"NeoGenomics: lung cancer testing","url":"https://www.neogenomics.com/providers/oncology-solutions/lung-cancer"}],"tags":["test"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["cgp","liquid-biopsy","reference-laboratories"],"targets":[],"drugs":[],"companies":["neogenomics"],"institutions":[],"pathways":[],"terms":["ngs","tmb","msi","hrd","ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: an alteration linked to a drug or trial is reported for the cancer type; a negative blood result does not rule out an alteration in the tumour."],"brand":"PanTracer","modality":"Comprehensive genomic profiling tests for solid tumours (tissue and blood)","mechanism":"Tissue sequencing of 517 genes in DNA and RNA, or blood sequencing of 514 genes in circulating tumour DNA, for single-nucleotide variants, insertions and deletions, copy number changes and fusions.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/neogenomics-pantracer/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/"}],"company":[{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/"},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}]}}